source
- Axiom Biosciences pursues Hong Kong IPO and novel stem cell platform amid funding challengesAxiom Biosciences is charting an unconventional financing path by targeting a public listing in Hong Kong, with a long‑term goal of listing on the Nasdaq. The company is developing multiple drug d…
- ‘Flying blind’: Why experts fear Treasury’s China biotech investment crackdown will backfireThe U.S. Treasury's COINS Act proposal aims to shield U.S. biotech from Chinese competition, but insiders warn it will backfire. As lawyers scramble to decipher an ambiguous ban on cross-border "jo…Fierce Biotech · 3d ago↗ source
- FDA grants accelerated approval for Rybrevant Faspro in recurrent/metastatic head and neck cancer